The short-term follow-up of patients with diabetes mellitus presenting with COVID-19.

• DOI: 10.25122/jml-2025-0027
• Publication Date: 2025-02-01
• Authors: Delia-Andreea Les...; Alin Kraft; Cosmin Moldovan; Dan Nicolae Ungur...; Nicolae Bacalbaşa
• Keywords: 2019-20 coronavirus outbreak; Betacoronavirus; Coronavirus Infections

The COVID-19 pandemic has disproportionately affected individuals with diabetes mellitus (DM), significantly increasing their risk of adverse outcomes. This retrospective study aimed to explore the underlying factors contributing heightened vulnerability DM severe COVID-19. We reviewed medical records patients diagnosed from August 2020 2022 and identified 60 equally divided into two groups. Group A (n = 30) included those an associated infection, while B served as control group without a infection. Inflammatory biomarkers, venous blood glucose levels, other parameters were assessed at hospital admission again after 14-day treatment period. Statistical analysis confirmed strong association between In treated Empagliflozin, correlations observed IL-1, TNF-alpha, IL-6, levels. Patients in did not show significant improvements inflammatory markers or control. contrast, first group, better interleukin levels demonstrated, suggesting higher success rate for that treatment. Our findings indicate Empagliflozin had limited efficacy managing long-term diabetes-related complications, it might offer benefits acute phase illness.